flupentixol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1211 2709-56-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flupentixol hydrochloride
  • flupenthixol
  • fluanxol
  • flupentixol
  • fluxanxol
  • flupentixol dihydrochloride
  • N-7009
  • flupentixol HCl
A thioxanthene neuroleptic that, unlike CHLORPROMAZINE, is claimed to have CNS-activating properties. It is used in the treatment of psychoses although not in excited or manic patients. (From Martindale, The Extra Pharmacopoeia, 30th ed, p595)
  • Molecular weight: 434.52
  • Formula: C23H25F3N2OS
  • CLOGP: 4.34
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 26.71
  • ALOGS: -5.04
  • ROTB: 6

Drug dosage:

DoseUnitRoute
6 mg O
4 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 4.14 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 34.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1964 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood prolactin abnormal 1271.32 101.96 210 3640 2869 63482303
Anosognosia 1270.54 101.96 211 3639 2985 63482187
Disturbance in social behaviour 1216.79 101.96 210 3640 3783 63481389
Sexual dysfunction 1198.39 101.96 210 3640 4149 63481023
Metabolic disorder 1114.51 101.96 210 3640 6293 63478879
Personality change 1043.72 101.96 201 3649 6772 63478400
Dystonia 857.04 101.96 192 3658 13627 63471545
Dyskinesia 805.09 101.96 215 3635 31787 63453385
Sedation 777.76 101.96 218 3632 38591 63446581
Suicide attempt 722.32 101.96 228 3622 60690 63424482
Blood glucose increased 589.82 101.96 212 3638 83544 63401628
Insurance issue 200.77 101.96 51 3799 6070 63479102
Drug ineffective 164.06 101.96 252 3598 1044513 62440659
Condition aggravated 160.16 101.96 156 3694 402061 63083111
Adverse drug reaction 155.76 101.96 82 3768 79632 63405540

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 446.26 106.27 89 2948 2458 34951436
Therapeutic product effect variable 431.36 106.27 86 2951 2370 34951524
Disinhibition 425.29 106.27 89 2948 3137 34950757
Obsessive-compulsive disorder 408.65 106.27 95 2942 5469 34948425
Akathisia 402.88 106.27 101 2936 8008 34945886
Suicide attempt 390.86 106.27 141 2896 38975 34914919
Euphoric mood 375.76 106.27 89 2948 5552 34948342
Increased appetite 361.34 106.27 91 2946 7338 34946556
Blood prolactin abnormal 238.08 106.27 45 2992 924 34952970
Anosognosia 237.90 106.27 45 2992 928 34952966
Disturbance in social behaviour 209.03 106.27 45 2992 1806 34952088
Therapeutic product effect incomplete 181.36 106.27 88 2949 50453 34903441
Metabolic disorder 171.49 106.27 45 2992 4238 34949656
Weight increased 168.72 106.27 103 2934 92930 34860964
Leukopenia 166.03 106.27 89 2948 62767 34891127
Leukaemia 163.55 106.27 44 2993 4559 34949335
Sexual dysfunction 163.17 106.27 47 2990 6256 34947638
Dyskinesia 151.64 106.27 61 2976 22352 34931542
Dyslipidaemia 150.89 106.27 46 2991 7442 34946452
Dystonia 141.98 106.27 48 2989 10797 34943097
Personality change 140.52 106.27 40 2997 5099 34948795
Obesity 137.70 106.27 49 2988 12829 34941065
Drug ineffective 133.63 106.27 179 2858 456572 34497322
Prescribed overdose 123.30 106.27 43 2994 10604 34943290

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood prolactin abnormal 1381.18 79.47 235 5253 3366 79735534
Anosognosia 1377.65 79.47 236 5252 3528 79735372
Disturbance in social behaviour 1305.55 79.47 235 5253 4735 79734165
Sexual dysfunction 1213.21 79.47 237 5251 7526 79731374
Metabolic disorder 1161.89 79.47 235 5253 8935 79729965
Personality change 1079.26 79.47 225 5263 9945 79728955
Dystonia 887.32 79.47 220 5268 21179 79717721
Dyskinesia 884.48 79.47 256 5232 44517 79694383
Suicide attempt 850.44 79.47 287 5201 82645 79656255
Sedation 804.17 79.47 246 5242 51649 79687251
Blood glucose increased 584.92 79.47 238 5250 114737 79624163
Drug ineffective 236.03 79.47 326 5162 1080587 78658313
Insurance issue 212.28 79.47 54 5434 5679 79733221
Adverse drug reaction 180.49 79.47 89 5399 66303 79672597
Condition aggravated 177.93 79.47 194 5294 500930 79237970
Akathisia 119.90 79.47 42 5446 13217 79725683
Antipsychotic drug level below therapeutic 117.18 79.47 25 5463 1213 79737687
Therapeutic product effect variable 105.13 79.47 25 5463 1984 79736916
Obsessive-compulsive disorder 103.75 79.47 31 5457 5896 79733004
Disinhibition 98.75 79.47 25 5463 2573 79736327

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AF01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Thioxanthene derivatives
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:65190 typical antipsychotic drugs
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.19 Basic
pKa2 4.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(1A) dopamine receptor GPCR ANTAGONIST Ki 8.40 IUPHAR IUPHAR
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.82 IUPHAR IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor IC50 8.65 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.10 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 7.06 PDSP
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.96 IUPHAR
D(1B) dopamine receptor GPCR ANTAGONIST Ki 8.10 IUPHAR
Histamine H1 receptor GPCR Ki 9.07 PDSP
D(4) dopamine receptor GPCR Ki 8.80 PDSP
Potassium channel subfamily K member 2 Ion channel IC50 5.70 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.05 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.75 CHEMBL
D(1A) dopamine receptor GPCR IC50 9.52 CHEMBL
Dopamine receptor GPCR IC50 8.52 CHEMBL

External reference:

IDSource
D01044 KEGG_DRUG
C0016367 UMLSCUI
CHEBI:5121 CHEBI
CHEMBL54661 ChEMBL_ID
CHEMBL42055 ChEMBL_ID
DB00875 DRUGBANK_ID
948 IUPHAR_LIGAND_ID
1745 INN_ID
2413-38-9 SECONDARY_CAS_RN
21HMQ851IS UNII
5281881 PUBCHEM_CID
235742 RXNORM
003477 NDDF
003479 NDDF
387567006 SNOMEDCT_US
442075003 SNOMEDCT_US
96220002 SNOMEDCT_US
D005475 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None